Back to resultsEfficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease
Primary Purpose
Alzheimer's Disease
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
LY451395
Sponsored by
About this trial
This is an interventional treatment trial for Alzheimer's Disease focused on measuring Alzheimer's Disease
Eligibility Criteria
Inclusion Criteria: Must have a clinical diagnosis of Alzheimer's Disease Must be at least 50 years of age Must fluently read and speak English Must have a reliable caregiver Exclusion Criteria: Has serious health problems other than Alzheimer's Disease Cannot swallow whole pills Has had a menstrual period in the last two years Takes insulin for diabetes Has taken Aricept, Reminyl, or Exelon in the last 5 weeks
Sites / Locations
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00051909
Brief Title
Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease
Official Title
Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease
Study Type
Interventional
2. Study Status
Record Verification Date
July 2006
Overall Recruitment Status
Completed
Study Start Date
November 2002 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
June 2003 (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Eli Lilly and Company
4. Oversight
5. Study Description
Brief Summary
Study of an investigational medication for the treatment of Alzheimer's Disease in patients who are not taking Aricept, Reminyl, Exelon.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alzheimer's Disease
Keywords
Alzheimer's Disease
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
200 (false)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
LY451395
10. Eligibility
Sex
All
Minimum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Must have a clinical diagnosis of Alzheimer's Disease
Must be at least 50 years of age
Must fluently read and speak English
Must have a reliable caregiver
Exclusion Criteria:
Has serious health problems other than Alzheimer's Disease
Cannot swallow whole pills
Has had a menstrual period in the last two years
Takes insulin for diabetes
Has taken Aricept, Reminyl, or Exelon in the last 5 weeks
Facility Information:
City
Beverly Hills
State/Province
California
Country
United States
City
Fresno
State/Province
California
Country
United States
City
Boca Raton
State/Province
Florida
Country
United States
City
Fort Lauderdale
State/Province
Florida
Country
United States
City
Miami Beach
State/Province
Florida
Country
United States
City
Boston
State/Province
Massachusetts
Country
United States
City
Oklahoma City
State/Province
Oklahoma
Country
United States
City
Tulsa
State/Province
Oklahoma
Country
United States
City
Wichita Falls
State/Province
Texas
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease
We'll reach out to this number within 24 hrs